Sitemap
- Current Trends and Growth Indications in the Global Anti-Infectives ...
- Hepatitis B Drug Can Compromise HIV Treatment
- The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance
- Drug used to prevent HIV transmission from mother to child damages DNA ...
- Does Less Trans Fat Make Food Healthier?
- Analysis: Gilead may get boost from Viread
- BARACLUDE(R) Treatment Demonstrated Greater Viral Load Reduction ...
- Can Liver Cancer Be Prevented?
- Bristol-Myers Squibb Company Reports First Quarter 2007 Financial ...
- Baraclude: occurrence of a resistant HIV variant in a patient co ...
- Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R ...
- Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R ...
- ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant ...
- BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of ...
- Bristol Cites Positive Baraclude Data
- Hepatitis - Highlights
- Studies Examine Effects Of Circumcision, Hepatitis B Treatment On HIV ...
- Hep B med may boost HIV
- HIV Turned into More Dangerous Mutant by Common Drug Category ...
- Hepatitis B Drug Triggers HIV Drug Resistance
- Hepatitis B drug boosts HIV-drug resistance
- Hepatitis B Drug Triggers HIV Drug Resistance
- Single Patient Shows Baraclude May Be Linked to Risk for Treatment ...
- The Canadian health agency said yesterday that it had received ...
- Hepatitis drug may be linked with resistant strain of HIV: Health ...
- Health Canada issues warning on use of Baraclude alone in HIV ...
- Sanofi merger could give Bristol a boost
- Bristol-Myers: Baraclude Leads To Greater Viral Reductions
- Generic Competition Plagues Bristol-Myers
- Bristol-Myers Boosts Guidance
- Bristol-Myers not for sale: interim CEO
- Hepatitis B
- Idenix Shares Fall on Downgrade
- FDA nod to Hepatitis Drug
- Entecavir Switch Effective in Lamivudine-Resistant Chronic Hepatitis B
- Rare heart surgery on 85-yr-old woman
- Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic ...
- Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic ...
- Fusion fashion
- US firm launches drug for Hepatitis
- Bristol says Plavix deal under U.S. criminal probe
- Windhover Information's 16th Annual Pharmaceutical Strategic Alliances ...
- Bacterial & Viral infections
- Adefovir - overview
- Hepatitis B
- Business Standard Columnists
- The Liver Meeting 2007: 58th Annual Meeting of the American ...
- NIH Issues Guidelines on Hepatitis B Management
- Tenofovir provides good hepatitis B virus suppression in HIV/HBV co ...
- BARACLUDE Data Show Low Resistance Over 5 Years In Nucleoside-Naive ...
- Another option for Hep B sufferers
- Hepatitis B vaccine scale-up and treatment of HIV/HBV co-infection ...
- New hepatitis B medicine funded
- Earnings Video Gallery
- Bristol-Myers posts 3.5 percent Q1 profit dip
- China seen fertile for pharmaceuticals
- XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of ...
- Drug deal not good enough: advocate
- User Drug Reviews - Baraclude Oral
- Drugs and Treatments - Baraclude Oral
- North Jersey Media Group providing local news, sports & classifieds for Northern New Jersey!
- Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients: Financial News - Yahoo!Finance
- Hepatitis B experts at loggerheads | The Australian
- The Sudbury Star - Ontario, CA
- North Bay News and Weather on BayToday.ca
- Error Message - Pharmaceutical Processing
- NEJM -- Entecavir Surprise
- PharmaLive: Corbett Worldwide Scores Two International Awards: The Result of A Creative Collision
- EndoNurse
- Ivanhoe's Medical Breakthroughs - Hep B Drug Could Interfere With HIV Meds
- Hepatitis is dangerous threat to HIV patients - Examiner.com
- Gilead's Epic Growth Story - Preview
- Challenges in Entecavir Drug Treatment
- wjz.com - Hopkins Doctors Warn Against Hepatitis, HIV Drug
- Hepatitis B Drug a Threat to Those With HIV - washingtonpost.com
- Pharmasset Presents Clevudine And Racivir Data At The International HIV Drug Resistance Workshop
- Corbett Worldwide Healthcare Communications :: Corbett Worldwide Scores Two International Awards: The Result of A Creative Collision
- BARACLUDE® (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared To Adefovir At 48 Weeks In Study Of Chronic Hepatitis B
- Baraclude(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients - PipelineReview.com | Business Intelligence Center
- PharmaLive: Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
- BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
- Bristol-Myers Squibb Company :: BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
- PharmaLive: Research and Markets: Gain an Insight into the Financial Performance of the Pharmaceutical Company - Bristol-Myers Squibb
- Briefing.com Business News: Market Report -- In Play (BMY) - MSN Money
- BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
- Drug Clinical Trials > Baraclude Treatment Demonstrated Great Viral Load Reduction
- DMCH doc attends international conference on liver diseases
- StreetInsider.com - Anadys Pharmaceuticals (ANDS) Higher After Positive Study Results
- Welcome to AJC! | ajc.com
- EndoNurse
- Daytrading, Eminis, Forex trading, Swing Trading TOP STORY - 537251
- MEMC Reports First Quarter Results
- CNW Telbec
- Cable Digital News - Cable Digital - Harmonic Reports Q1 - Telecom News Wire
- Wendy's International, Inc. Announces 2007 First-Quarter Results - QSR Magazine
- CNW Telbec
- Harmonic Announces First Quarter Results
- Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results
- PharmaLive: Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results
- StockerYale Announces First Quarter 2007 Financial Results
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532539
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532724
- Bristol-Myers Squibb's Baraclude to Dominate the Hepatitis B Virus Market through 2015
- drugnewswire.com
- drugnewswire.com
- Decision Resources, Inc. :: Bristol-Myers Squibb's Baraclude to Dominate the Hepatitis B Virus Market through 2015
- Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program
- StreetInsider.com - StreetInsider.com Unusual 11 Mid-Day Movers 04/13/2007
- StreetInsider.com - The Dow Gained 59 Points, Nasdaq Added 12
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532126
- ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants
- PharmaLive: ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants
- StreetInsider.com - Anadys Pharmaceuticals (ANDS) Higher After Positive Study Results
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532513
- ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants - PipelineReview.com | Business Intelligence Center
- BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
- Access to articles : Nature Reviews Drug Discovery
- HIV and Hepatitis Co-Infections Challenging - CME Teaching Brief® - MedPage Today
- Bloomberg.com: Worldwide
- Wall Street shows some sign of life - JAMAICAOBSERVER.COM
- KVOA News 4, Tucson, Arizona - Stocks mixed and little changed
- CNNMoney.com Market Report - Apr. 13, 2007
- Bloomberg.com: U.S.
- Bloomberg.com: U.S.
- Bloomberg.com: U.S.
- Bloomberg.com: Worldwide
- Stocks climb on higher profit forecasts
- Briefing.com Business News: Market Report -- In Play (BMY) - MSN Money
- PharmaLive: Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
- Bristol Myers Squibb initiated with "market perform" | newratings.com
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532539
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532724
- Four-Year Data Demonstrate Continued Low Incidence Of BARACLUDE® (entecavir) Resistance In Nucleoside-naive Chronic Hepatitis B Patients
- Bristol cites positive Baraclude data
- US FDA reviewer supports new use for Bristol drug| News| Regulatory News| Reuters
- Latest News | News | Hemscott
- EndoNurse
- Bristol-Myers Squibb :: BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
- Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
- Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
- BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment - PipelineReview.com | Business Intelligence Center
- Bristol-Myers Squibb Company :: Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
- BARACLUDE® (entecavir) Therapy Resulted In Undetectable Levels Of Hepatitis B Virus In Cohort Of Patients Who Re-Started Treatment
- Bristol Cites Positive Baraclude Data | Chron.com - Houston Chronicle
- Factor V; Hepatitis B - Dateline Florida
- Log In Problems
- Log In Problems
- Johns Hopkins Gazette | March 12, 2007
- The Bay Area Reporter Online | New risk with hepatitis B drug
- Welcome to AJC! | ajc.com
- Newindpress.com - Login Archives
- Hepatitis B drug triggers HIV resistance - Pharmaceutical Business Review
- Recent Releases | Studies Examine Effects of Circumcision, Hepatitis B Treatment on HIV/AIDS - Kaisernetwork.org
- Aidsmap | CROI: Anti-HBV drug entecavir also active against HIV and promotes antiretroviral resistance
- www.exduco.net - Graduate schools and programs guide
- Hepatitis B Drug Triggers HIV Drug Resistance
- CROI: HIV Resistance Linked to Hepatitis Drug - CME Teaching Brief® - MedPage Today
- Facts & Comparisons: Revised Baraclude Labeling Approved
- PharmaLive: Baraclude (entecavir) Occurrence of a resistant HIV variant in a patient co-infected with HIV and HBV
- Gay News From 365Gay.com
- News - Antiviral Drug Linked to Development of Treatment-resistant HIV
- CNW Telbec
- More Baraclude News Articles...
- Investigational agent promising for hepatitis B.(Gastroenterology): An article from: Internal Medicine News
- FDA approves entecavir for chronic hepatitis B.(Rx): An article from: Internal Medicine News
- Entecavir approved for chronic hepatitis B.(Infectious Diseases): An article from: Family Practice News
- Hepatitis B treatment may lead to HIV resistance.(Across Specialties)(Clinical report): An article from: Clinical Psychiatry News
- FDA panel: study hepatitis B drug in children: entecavir was approved for chronic HBV infection therapy in adults subsequent to the panel meeting.(Infectious Diseases): An article from: Pediatric News






